Meningiomas are common central nervous system tumors; however, the mechanisms underlying their pathogenesis are largely undefined. In this report, we demonstrate that a third Protein 4.1 family member, Protein 4.1R, functions as a meningioma tumor suppressor. We observed loss of Protein 4.1R expression in two meningioma cell lines (IOMM-Lee, CH157-MN) by Western blotting as well as in 6 of 15 sporadic meningiomas by immunohistochemistry and fluorescence in situ hybridization. In support of a meningioma tumor suppressor function, Protein 4.1R overexpression resulted in reduced IOMM-Lee and CH157-MN cell proliferation. Similar to the Protein 4.1B and merlin tumor suppressors, Protein 4.1R membrane localization increased significantly under conditions of growth arrest in vitro. Lastly, we show that Protein 4.1R interacted with a subset of merlin/Protein 4.1B interactors including CD44 and ␤II-spectrin. Collectively, these results suggest that Protein 4.1R functions as an important tumor suppressor in the molecular pathogenesis of meningioma.
Introduction
The two most common central nervous system tumors affecting adults are astrocytomas (gliomas) and meningiomas. Compared to the gliomas, relatively little is known about the molecular genetic events which are important in the molecular pathogenesis and malignant progression of sporadic meningiomas. One of the most common events associated with meningioma tumorigenesis is chromosome 22q deletion and inactivation of the neurofibromatosis 2 (NF2) gene (Ruttledge et al., 1994; Gutmann et al., 1997; Huynh et al., 1997; Leone et al., 1999; Ueki et al., 1999) . Additional events observed in meningiomas include chromosome 1p, 3p, 6q, 10q, and 14q deletions (Leone et al., 1999; Weber et al., 1997; Menon et al., 1997; Simon et al., 1995; Perry et al., 1996) . These regions are thought to contain tumor suppressor genes involved in malignant progression, since these deletions are most frequently seen in higher grade meningiomas (Schneider et al., 1995; Simon et al., 1995; Weber et al., 1997; Lamszus et al., 1999; Leone et al., 1999; Cai et al., 2001a) . In addition, p16 (CDKN2A) inactivation and PS6K (17q23) amplification likely represent late alterations associated with anaplasia (Tse et al., 1998; Bostrom et al., 2001; Cai et al., 2001b) . Chromosomal gains involving 12q, 15q, 17q, and 20q have also been reported (Simon et al., 1995; Weber et al., 1997) .
Since individuals affected with NF2 are at an increased risk of developing meningiomas, inactivation of NF2 has been hypothesized to represent a critical initiating event in NF2-associated meningioma formation. Loss of NF2 expression also appears to be an early event in sporadic meningioma pathogenesis (Stemmer-Rachamimov et al., 1998;  
